Use of the tumor necrosis factor-blockers for Crohn's disease

Table 15 Therapeutic gain of adalimumab maintenance of response and remission (%)

Study	Assessment week	ADA2	ADA3	PL	Therapeutic gain
	Maintenance
CHARM	Response (CDAI ↓≥ 100 pts)
	26	521	521	27	251-251
	56	411	481	17	241-311
	Response (CDAI ↓≥ 70 pts)
	26	541	561	28	261-281
	52	431	491	18	251-311
(Classic II)	Response (CDAI ↓≥ 100 pts)
	24	84	941	61	23-331
	56	79	891	56	23-331
	Remission (CDAI ↓≥ 100 pts)
	26	401	461	17	231-291
	56	361	411	12	241-191
	Remission (CDAI ↓≥ 70 pts)
	24	95	94	83	12-11
	56	79	89	72	7-17
	Remission
	4	95	1001	89	6-111
	12	901	891	56	441-331
	24	841	941	50	341-441
	32	841	1001	39	451-611
	48	74	94	44	30-50
	56	79	83	44	35-39

¹Significant difference;

²40 mg at week 0, 20 mg at week 1;

³80 mg at week 0, 40 mg at week 2. CDAI: Crohn’s disease activity index; PL: Placebo; pts: Points; ADA: Adalimumab; CHARM: Crohn's trial of the fully human antibody adalimumab for remission maintenance.